Press Release

ASKA Pharmaceutical Co., Ltd.

Announcement regarding the release of the GnRH antagonist “RELUMINA® Tablets 40mg”

TOKYO, February 26th, 2019 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that the GnRH antagonist “RELUMINA® Tablets 40mg”(generic name: Relugolix, hereinafter " RELUMINA") has been listed in the National Health Insurance drug price list as of today and will be released on March 1st.

RELUMINA was originally developed by Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka, President: Christophe Weber, hereinafter "Takeda") and was licensed-in from Takeda as a GnRH antagonist for indications in obstetrics and gynecology.

The Ministry of Health, Labour and Welfare granted manufacture and marketing approval for RELUMINA as a treatment agent for uterine fibroid related symptoms on January 8th 2019 and was listed in the National Health Insurance drug price list as of February 26th, 2019.

By launching RELUMINA, ASKA will be able to provide new treatment options to patients with uterine fibroids and will contribute to improving their QOL.

The impact of this matter on the business outcome has already been incorporated into the business forecast for the fiscal year ending in March, 2019 which was announced on February 4, 2019.

<Product overview>

Product name	RELUMINA® Tablets 40mg
Generic name	Relugolix
Indication	To improve the following symptoms related to uterine fibroids: menorrhagia, lower abdominal pain, back pain, anemia.
Dose	Generally, 40mg of Relugolix once a day before meal via PO for adults. First dose should be given between the 1st ~ 5th day of the menstrual cycle.
Drug price	¥ 905.7
Package	100 tablets (10 tablets×10)
Drug price listed	February 26th, 2019
Product release	March 1st, 2019
Marketing Authorization Holder	Takeda Pharmaceutical Company Limited
Sold by	ASKA Pharmaceutical Co., Ltd.